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Impaired ability to undergo programmed cell death in
response to a wide range of external stimuli acquires
melanomas a selective advantage for progression and
metastasis as well as their notorious resistance to therapy.
Better understanding of mechanisms that govern apoptosis
has enabled identification of diverse routes by which
melanomas manage to escape stimuli of apoptosis.
Changes at genomic, transcriptional and post-transla-
tional levels of G-proteins and protein kinases (Ras, B-
Raf) and their transcription factor effectors (c-Jun,
ATF2, Stat3 and NF-jB) affects TNF, Fas and TRAIL
receptors, which play important roles in acquiring
melanoma’s resistance to apoptosis. Here, we summarize
our current understanding of changes that alters the
regulation of death receptors during melanoma develop-
ment.
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Introduction
Overview of apoptotic signaling
Programmed cell death (apoptosis) plays an important
role in development, homeostasis and anticancer protec-
tion of multicellular organisms. Effective mechanisms
for induction of programmed cell death in response to
hormone-, immune- or stress-induced signaling are
known to exist among most metazoan. Yet, it is the
stochastic somatic cell mutations and epigenetic silen-
cing of genes that regulate growth and death pathways,
which play key roles in cancer development.
Apoptosis is characterized by distinct morphological
and biochemical changes that take place upon the
activation of a family of caspases, which are usually
expressed as inactive zymogenes and require proteolytic
processing upon initiation of apoptosis (Nicholson,
1999). Two main apoptotic pathways result in activa-
tion of caspases. The first is induced upon the ligation
of transmembrane death receptors with their cognate
ligands, resulting in the activation of caspase-8 and
-10, with concomitant activation of effector caspase-3
and -7. Six distinct death receptors are known and
include TNF receptor-1 (TNF-R1), Fas (APO-1/CD95),
TRAMP or death receptor-3 (DR3), TRAIL receptor-1
and receptor-2 (TRAIL-R1/DR4, TRAIL-R2/DR5)
and death receptor-6 (DR6). Among these, TNF-R1,
TRAIL, and Fas receptors and their ligands have been
extensively investigated (Nagata, 1997, 1999; Krammer,
2000; Daniel et al., 2001; Igney and Krammer, 2002;
Johnstone et al., 2002). Studies of the death-inducing
signaling complex (DISC) revealed that trimerization of
Fas and TRAIL receptors leads to recruitment of the
Fas-associated death domain (FADD), an adaptor
molecule that recruits and activates caspase-8. In the
case of TNF-R1 ligation, an additional adaptor
molecule, TRADD, which binds TNF-R1 and FADD,
is involved in formation of the death-induced signaling
complex.
In the human body, Fas ligand (FasL) and TNFa are
produced by activated lymphocytes and macrophages,
respectively, whereas TRAIL is expressed by different
cell types. In contrast, TNF-R1 and Fas receptors are
widely expressed by normal cells whereas TRAIL
receptors have more restricted distribution. Further,
whereas the main function of Fas and TRAIL receptors
is to induce the death-signaling pathway, TNF-R1’s
ability to elicit death signals is normally suppressed by
NF-kB-dependent expression of antiapoptosis genes,
and the TNF-R1/TRAF2/NF-kB/JNK/c-Jun signaling
pathways (Baud and Karin, 2001).
The second apoptosis network, which can be initiated
by various forms of stress, requires caspase-2-dependent
disruption of the mitochondrial membrane (Lassus et al.,
2002) and release of mitochondrial proteins, including
cytochrome c. Mitochondrial membrane permeabiliza-
tion occurs as a result of altered balance between
proapoptosis (BH3-only members of the Bcl-2 family,
such as Bid or Bim) and antiapoptosis members of
the Bcl-2 family (such as Bcl-2, Bcl-XL; Adams and
Cory, 1998). Upon its release, cytochrome c cooperates
with Apaf-1 to activate caspase-9, thereby initiating
the amplification loop of the effector caspase cascade
(Martinou and Green, 2001; Zamzami and Kroemer,
2001; Kumar and Vaux, 2002). In certain conditions,
crosstalk between the two apoptosis networks exist:
Bid is cleaved by active caspase-8 following death
receptor stimulation and translocates to the mitochon-
dria, where it initiates the mitochondrial apoptosis
pathway (Scaffidi et al., 1999; Johnstone et al., 2002).
Changes in availability of important components of
this cascade were noted in the course of melanoma
progression, as exemplified by the downregulation
of Apaf-1 expression because of its hypermethylation
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in 40% of advanced melanomas (Soengas et al., 2001).
Mitochondrial pathways in melanoma apoptosis are
reviewed by Soengas and Lowe in this issue.
Here, we focus on the key death signaling pathways
and their regulation in the course of melanoma
development. We further point to means that can be
considered as targets for sensitizing resistant melanomas
to therapy.
Altered signal transduction in melanoma: implication to
death signaling cascades
The emerging picture, based on recent studies, suggests
that signal transduction and the corresponding tran-
scription factor effectors are among the key contributors
to melanoma development and progression, based
on the frequent changes found in the corresponding
members of Ras and Raf signaling cascades. A high
incidence of mutations within these pathways has
been reported to exist in human melanomas. Whereas
about 20% of melanomas appear to carry mutation in
the N-ras oncogene (Herlyn and Satyamoorthy, 1996;
Castellano and Parmiani, 1999), over 60% were recently
reported to contain mutation within the B-Raf gene
(Davies et al., 2002). In both cases, mutation renders
both kinases constitutively active thereby eliciting
constant signal towards the activation of down-
stream signaling components and the corresponding
transcription factors substrates, including NF-kB,
c-Jun and ATF2. Constitutively active Rac and ERKs,
which correspond to the immediate target of Ras and
B-Raf, respectively, were often seen in melanomas
and other tumor types, and considered as target for
therapy (Weinstein-Oppenheimer et al., 2000; Fan
and Chambers, 2001; Hagemann and Blank, 2001;
Herr and Debatin, 2001; Mandic et al., 2001). Our
former studies have demonstrated Rac1 ability to
override PI3K signaling, which would otherwise result
in upregulation of Fas surface expression (Ivanov et al.,
2002). Similarly, the role of ERK in eliciting antiapop-
totic signals has been well established (reviewed in
Herr and Debatin, 2001; Hagemann and Blank, 2001),
thereby providing important insights into mechanisms
underlying antiapoptotic signals in melanomas. Adding
to these major impairments, the occurrence in PTEN
mutation or epigenetic changes which inactivate
PTEN, which renders PI3K constitutively active to
elicit antiapoptotic signals (Zhou et al., 2000;
Celebi et al., 2000), strongly suggest that melanomas
acquired the ability to attenuate signals that would
normally lead to apoptosis, utilizes multiple pathways.
Figure 1 highlights the impaired signaling cascades
reported so far to exist in melanomas, and their
downstream targets.
Transcription factors as master regulators of apoptosis
cascades
Four families of transcription factors (NF-kB/Rel, AP1/
ATF2, Stat and p53) appear to serve as central
regulators of cell’s ability to commit towards apoptosis



























Figure 1 Mutated signal transduction components in melanoma. Three major cascades that are affected in the human melanoma
include Ras, B-Raf and PTEN, which were shown to harbor mutations in advanced melanomas. Consequently, the downstream
effector kinases and corresponding transcription factors that are implicated in the death signaling cascade are activated thereby
providing constitutive antiapoptotic signals
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Shaulian and Karin, 2002). Transcriptional output is
highly dependent on the available factors and assembly
of heterodimers or their proximal binding on specific
promoters. Here, we describe three examples where the
ability of melanoma to undergo apoptosis is directly
dictated by the nature of some of the available
transcriptional complex. Figure 2 highlights the major
transcriptional players known to attenuate apoptosis in
advanced melanomas.
Nuclear factor kB (NF-kB): the double sword fac-
tor As a sequence-specific transcription factor NF-kB
coordinates expression of over 150 genes involved in
regulation of inflammation, the immune response, cell
proliferation and apoptosis. Of the five members of the
NF-kB family in mammals (p50/p105, p52/p100, p65/
RelA, c-Rel and RelB), the prevalent form of NF-kB is
the heterodimer of the p65/RelA and p50 subunits. Via
its regulation of expression of proapoptosis and anti-
apoptosis genes, NF-kB is a key contribution to the
balance between cell survival and apoptosis. In its
antiapoptosis capacity, NF-kB attenuates TNFa-in-
duced apoptosis (Beg and Baltimore, 1996); in this case
NF-kB upregulates expression of c-IAP1, c-IAP2
(Deveraux et al., 1998), TRAF-1, TRAF-2 (Baldwin,
1996), c-FLIP (Micheau et al., 2001) and BclxL genes
(Ravi et al., 2001), each of which has been shown to
exert potent antiapoptosis effects. In contrast, NF-kB’s
ability to induce transcription of TNFR1 and TNFa
(Baldwin, 1996), TRAILR1, TRAILR2 (Ravi et al.,
2001) and Fas (Chan et al., 1999; Ivanov and Ronai,
2000b; Zheng et al., 2001) are associated with its
proapoptosis signals.
Suppression of NF-kB activity switches the prevailing
death pathway in melanomas from FasL to TNF-
mediated apoptosis (Ivanov et al., 2001b). Alternatively,
TRAIL-induced apoptosis is suppressed by NF-kB-
dependent transcription in tumor cell lines (Ravi et al.,
2001), including melanomas (Franco et al., 2001),
similar to NF-kB’s effect on TNFa-induced apoptosis.
ATF2/c-Jun: transcriptional switch and melanoma resis-
tance Early-phase-melanoma-derived cells have low
basal yet inducible levels of AP-1 (Jun–Fos) activity.
This activity markedly increases during tumor progres-
sion (Rutberg et al., 1994; Ivanov et al., 2000a).
Members of the AP-1 family, including c-Jun, have
been implicated in controlling the balance between cell
survival and death (Karin and Lin, 2002; Shaulian and
Karin, 2002).
Recent studies from our laboratory provide an
example of ATF2/c-Jun-dependent transcription that
dictates melanoma cells’ resistance to apoptosis. ATF2















Figure 2 Transcription factors implicated in attenuated death signaling in melanoma. Each of the three major apoptotic cascades is
altered because of a different transcriptional switch. TNF signaling is affected by NF-kB, which can be upregulated either by elevated
TRAF2 activity or constitutive ERK signaling because of mutated B-Raf. NF-kB in turn suppress caspases required for both TNF-
and Fas-mediated apoptosis, and inhibit Fas trafficking because of activation of FAP-1 that inhibits Fas export to the cell surface.
Activation of TRAF2 and p38 result in the elevated ATF2 activity, which also elicits antiapoptotic signal. TRAIL, which is expressed
at higher levels in advanced melanomas, is inhibited because of the elevated expression of decoy receptors that blocks TRAIL
association with the receptor
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Jun2-bearing promoter sequences (van Dam et al., 1998;
van Dam and Castellazzi, 2001). ATF2 is upregulated in
advanced melanomas, somewhat similar to what has
been found for c-Jun (our own unpublished data).
Inactivating ATF2 in melanoma-driven cell lines by the
use of dominant-negative or transcriptionally inactive
forms is sufficient to sensitize melanoma cells to
treatment in vitro (Ronai et al., 1998). Our search for
an ATF2-derived peptide that may interfere with
endogenous ATF2 function to enable sensitization of
melanoma to apoptosis upon treatment led us to
identify a 50 amino-acid (aa) sequence from the amino
terminal ATF2 (aa 50–100) domain (Bhoumik et al.,
2001). Expression of this peptide not only sensitized
melanoma cells to apoptosis in response to a wide range
of treatments that otherwise do not affect this tumor
type, but efficiently inhibited growth and metastasis in
different mouse models in vivo (Bhoumik et al., 2002). In
evaluating the mechanism underlying the ATF2 peptide
activities, we found that it efficiently inhibits ATF2’s
own function while causing marked increase in the
activity of c-Jun. Increased c-Jun activity in the absence
of ATF2 provides another microenvironment that
suffices to sensitize melanoma (and other tumor types;
our own unpublished data) to treatment. Inhibition of
ATF2 per se results in increased activity of c-Jun in
melanoma cells, highlighting the basic premise of this
peptide activity. Consequently, the set of genes ex-
pressed has been altered, including the apoptosis path-
way that has been switched towards the TRAIL
pathway (Bhoumik et al., 2002). In all, these findings
highlight the importance of transcriptional regulation,
which enables the sensitization of melanoma to treat-
ment and inhibits their growth and metastasis in vivo.
p53; the tumor suppressor that may malfunction in
melanoma The tumor suppressor protein p53 plays
important role in the regulation of the mitochondrial
apoptotic pathway by transcriptional activation of
proapoptosis Bcl-2 family members (such as Bax,
Bam, Puma and Noxa; reviewed in Bargonetti and
Manfredi, 2002; Alarcon-Vargas and Ronai, 2002) and
by repression of antiapoptosis Bcl-2 family proteins. p53
also promotes death receptor-mediated apoptosis by
trans-activation of Fas and TRAIL-R2 transcription
(Johnstone et al., 2002). Although p53 is not mutated in
the majority of human melanomas, evidence to support
impaired transcriptional activities of p53 exists (Satya-
moorthy et al., 2000). An overall increase in p53
phosphorylation was observed in human melanomas,
suggesting that it may result in the activation of a
different subset of genes, when compared with non-
transformed cells (Minamoto et al., 2001). Further
studies are required to define changes that may alter
p53 function in advanced melanomas.
Fas death cascade in melanoma
Changes in Fas expression and activity have been often
reported to take place in human melanomas, as in other
tumor types (Hug, 1997; Shin et al., 1999; Bullani et al.,
2002). The Fas-mediated apoptosis cascade requires that
Fas receptor be appropriately expressed on the cell
surface and be available for association with Fas ligand.
Fas–FasL association results in receptor trimerization
and induction of the downstream cascade involving
caspase-8 and -3 (Nagata, 1999; Krammer, 2000).
However, in a large percentage of tumors Fas is not
expressed appropriately, as reflected in fewer molecules
per cell or a substantial decrease in the relative fraction
of cells that express Fas on the cell surface (Igney and
Krammer 2002; Reichmann, 2002).
Downregulation of Fas/CD95 in lymphoid and solid
tumors is often associated with resistance to drug-
induced cell death (Muschen et al., 2000; Straus et al.,
2001). Similarly, human malignant melanomas that lack
expression of Fas have a poor prognosis (Helmbach
et al., 2001). Of interest, whereas the Fas-apoptotic
pathway is active in early- and intermediate-phase
melanomas, it is often impaired in highly metastatic
late-phase melanomas (Owen-Schaub et al., 1998; Chan
et al., 1999; Bullani et al., 2002). Inverse correlation
between Fas expression and metastatic potential was
also observed for osteosarcoma cells (Worth et al.,
2002).
Downregulation of Fas signaling can be attributed to
changes at the genomic, transcriptional and post-
translational levels. Mutations in the death domain of
Fas have been reported to take place in 7% of metastatic
melanomas (Shin et al., 1999), resulting in an abnormal
protein that exhibits abrogated association with FADD
and procaspase-8, which are required for eliciting
activation of downstream effector caspase-3. Somatic
mutations in Fas, FADD and caspase 10 genes were also
found in different hematopoietic malignancies (Kitada
et al., 2002; Shin et al., 2002).
A more common event in melanomas relates to
transcriptional downregulation of Fas expression. Silen-
cing of Fas receptor promoter was reported to take
place by cooperating transcription factors, as well as
because of the hypermethylation of its promoter.
Regulation of Fas transcription has been shown
to depend on NF-kB (Chan et al., 1999; Ivanov and
Ronai, 2000b; Zheng et al., 2001), p53 (Owen-Schaub
et al., 1995) and additional transcription factors such as
Stat1 and Stat3. Common to these transcription factors
is their positive effect on Fas receptor expression.
However, cooperation of some, as shown for
c-Jun and Stat3, results in suppression of Fas transcrip-
tion. FasR promoter consists of three AP1-binding
and three GAS elements, which provide the framework
for Stat3 interaction with c-Jun, resulting in Fas
suppression. Mutations within the promoter that
abrogate the binding of either Stat3 or c-Jun are
sufficient to increase Fas transcription. Fas expression
could be rescued in melanomas that exhibit very low
levels of Fas expression, by inhibition of Stat3 or c-Jun,
thereby abrogating cooperation between the two onco-
genes (Ivanov et al., 2001a). Of interest, cooperation
between Stat3 and c-Jun to silence Fas promoter is
not limited to tumor cells, as fibroblasts that lack
c-Jun or Stat3 also exhibited higher levels of Fas that
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could be suppressed upon re-expression of the lacking
factor. Cooperation between Stat3 and c-Jun to
suppress FasR transcription was found to depend
on PI3K signaling. Inhibition of PI3K activities via
the pharmacological inhibitor or dominant-negative
forms of p85 or PKB was sufficient to increase
transcriptional activities of Jun and Stat3, thereby
resulting in decreased Fas transcription. PI3K nega-
tively regulates Stat3 and c-Jun via its effect on
intermediate kinases, including Rac1 pathway (Ivanov
et al., 2002). Whereas in normal cells PI3K attenuates
most of Stat3–Jun-mediated silencing, thereby enabling
Fas transcription, in tumor cells this pathway is over-
ridden because of the constitutive activities of down-
stream components including members of the Rac1,
Rho and possibly Raf families because of activating
mutation in Ras (reviewed in Herlyn and Satyamoorthy,
1996; Castellano and Parmiani, 1999) and B-Raf genes
(Davies et al., 2002).
Methylation of Fas promoter was also reported to
take place in association with oncogenic Ras, resulting
in lower levels of Fas transcripts (Peli et al., 1999). A
more recent study excluded a critical role of hyper-
methylation in the regulation of FasR expression
(Santourlidis et al., 2001).
Another means of attenuating Fas expression is its
selective inhibition from expression on the cell surface.
Certain melanomas exhibit appropriate expression of
Fas, and yet this Fas is primarily localized within the
cytoplasmic compartment of the cell, and thus cannot
reach the cell surface, where it is required to function.
Recent studies in our lab linked Fas-associated phos-
phatase-1 (FAP-1; Sato et al., 1995) to the regulation
of Fas trafficking. Overexpression of FAP-1, which
is often reported in human tumors, results in inhibi-
tion of Fas cell surface expression (Krasilnikov et al.,
2003).
Specific viral infection, as shown for adenovirus, is
often accompanied by removal of Fas receptor from the
cell membrane followed by its accelerated degradation,
which is mediated by adenovirus E3 proteins (Tollefson
et al., 1998; Elsing and Burgert, 1998), thereby pointing
to another mechanism that selectively targets Fas
removal from the cell surface. Figure 3 highlights the
components of the Fas cascades that were found to be
altered in human tumors, resulting in efficient inactiva-
tion of the Fas death pathway.
A prerequisite to Fas death signaling is the avail-
ability of its ligand. FasL gene transcription is primarily
seen in several types of normal cells in eyes, testis, and T
lymphocytes (Nagata, 1999; Krammer, 2000). However,
stress, such as irradiation or DNA damage by different
types of anticancer drugs, induces FasL transcription.
The critical step in FasL induction is dependent on c-
Jun activation by JNK, followed by c-Jun-dependent
transcription via two AP-1 binding sites within the
FasL-promoter (Zhang et al., 2000). As a result, stress-














































Figure 3 Altered Fas signaling in human melanoma. Fas signaling is altered in advanced melanomas at multiple levels. Those include
mutations within the Fas gene, downregulation of Fas transcription because of silencing of its promoter, inhibition of Fas trafficking to
the cell surface, or inhibition of caspases activation/activity by activated NFkB. FasL which is required for Fas activation is usually
over produced in melanomas, resulting in immunosuppression because of its sequestering effects on T cells
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step in apoptosis of certain tumor cells in response to
treatment with anticancer drugs (Eichhorst et al., 2000;
Kolbus et al., 2000; Kirchhoff et al., 2002). FasL
transcription is also regulated by NF-kB (Ivanov et al.,
1997; Kasibhatla et al., 1998; Matsui et al., 1998; Hsu
et al., 1999a, b; Li-Weber et al., 2000), NF-AT (Holtz-
Heppelmann et al., 1998), EGR-3 (Mittelstadt and
Ashwell, 1998) and SP1 (McClure et al., 1999),
transcription factors that are often upregulated in
human tumors including melanomas.
High levels of FasL expression by malignant melano-
mas has been implicated in suppression of the immune
response during cancer progression (Hahne et al., 1996;
O’Connell et al., 1999; Andreola et al., 2002). Compara-
tive studies of Fas and FasL expression revealed
downregulation of Fas and upregulation of FasL
expression during melanoma progression (Ekmekcioglu
et al., 1999; Soubrane et al., 2000). An inverse
correlation between expression of FasL and that of
Fas has been also found in melanoma-derived cell lines.
Changing the balance between the ligand and the
receptor so that both are expressed often resulted in
efficient sensitization of the melanoma cells to apoptosis
(Ivanov et al., 2001a, 2002). For example, transfection
and overexpression of exogenous Fas in melanoma cells
with high levels of endogenous FasL induced efficient
cell death (Aragane et al., 2000). Similarly, expression of
exogenous FasL in tumor cells that express endogenous
Fas receptor has often been tested as a possible
anticancer treatment (Arai et al., 1997). However, in
vivo sensitization has been hampered because of the
inability to target selectively the tumor cells, thereby
causing an efficient apoptosis in nontransformed cells
(Aoki et al., 2000).
TRAIL and apoptosis in melanoma
When compared with nontransformed cells, cancer cells
are more sensitive to TRAIL-induced apoptosis follow-
ing exposure to TRAIL/Apo2 ligand treatment (Ashke-
nazi et al., 1999; Marsters et al., 1999). Selective
sensitization of tumor cells to TRAIL-induced apoptosis
can often be attributed to greater expression of the
TRAIL receptor. Along these lines, cells that express
high levels of TRAIL receptors, as shown for TRAIL-
R2, are also highly sensitive to TRAIL-mediated cell
death. The latter finding was confirmed in a large panel
of cultured melanoma cells whose TRAIL receptor
expression and TRAIL-dependent apoptosis were ex-
amined (Griffith et al., 1998; Zhang et al., 1999). For
this reason, TRAIL has been the preferred candidate for
use in a therapeutic approach, given the distinct
difference in its expression when compared with non-
transformed cells. So far, treatment of melanomas (like
other tumor types) with TRAIL-based therapy has
yielded promising results (Thomas and Hersey, 1998;
Ashkenazi et al., 1999; Walczak et al., 1999; Pollack
et al., 2001).
However, a large fraction of tumors, including
melanomas, decrease expression or activities of TRAIL,
resulting in attenuated TRAIL-dependent apoptosis.
Some melanoma cells have completely lost expression of
TRAIL receptors, presumably as a result of loss of
chromosome 8p22–21. In addition, loss of TRAIL
receptor expression may also be attributed to an
epigenetic silencing mechanism. Furthermore, at least
two decoy receptors bind TRAIL without the ability to
induce apoptosis, thereby pointing to an additional layer
of regulation for the TRAIL apoptosis cascade (Kram-
mer, 2000; Hersey and Zhang, 2001). Interestingly, some
melanoma cell lines substantially increased basal levels
of TRAIL expression upon expression of Stat3b, a
dominant-negative form of Stat3 implying that Stat3
negatively regulates TRAIL transcription. Increased
expression and secretion of TRAIL in Stat3b-trans-
fected B16 mouse melanoma cells resulted in elevated
apoptosis of these cells in vivo (Niu et al., 2001). It is of
interest that adenovirus infection results in the binding
of adenoviral proteins to the TRAIL receptors resulting
in their subsequent internalization and degradation
(Tollefson et al., 2001).
TNFa signaling in the regulation of apoptosis
A major apoptosis signaling pathway relies on TNFa
andthenetworkassociatedwithTNFR-1signaling.TNFa
regulates inflammation, survival, proliferation and
apoptosis by activating the membrane-bound receptors,
TNF receptors 1 and 2 (TNFR) (Ashkenasi and Dixit
1998; Locksley et al., 2001; Chen and Goeddel, 2002).
Similar to Fas, TNF-R1 is trimerized upon the binding
of its ligand, TNFa. Upon such binding there is efficient
recruitment of adaptor protein TRADD and of TRAF2,
which binds to NH2-terminal domain portion of
TRADD (Hsu et al., 1996) and recruits the death
effector domain (DED) proteins such as FADD and
receptor interacting protein (RIP). FADD contains
DED that binds to the DED of caspase-8, resulting in
cleavage of procaspase-8 into its active form – caspase-8
and subsequent apoptosis (Hsu et al., 1996; Morgan
et al., 2002). However, unlike Fas, which mainly
functions as stimulator of the apoptosis cascade,
signaling from TNF-R1 often results in inhibition of
apoptosis through the efficient activation of p38, IKK
and NF-kB (Chen and Goeddel, 2002). TNFR-1-
mediated NF-kB activation results in activation of c-
FLIP or cIAP, which efficiently inhibits caspase-8
activation (Baud and Karin, 2001; Micheau et al.,
2001), or of Bcl-xL, which attenuates cytochrome c
release, thereby attenuating apoptosis that would have
otherwise been elicited from the same receptor (Igney
and Krammer, 2002). The balance between the pro- and
antiapoptotic signals within the TNF-R1 framework is
central in dictating whether TNF-R1 activation results
in TNF-dependent cell death (Figure 4).
One of the important mediators of TNFR-1-depen-
dent antiapoptosis signals is TRAF2, which is recruited
to TNF-R1 via TRADD upon TNFa stimulation
(Rothe et al., 1995; Chen and Goeddel, 2002). TRAF2
in turn elicits activation of major stress-signaling
cascades, resulting in activation, of NF-kB and NF-
kB-dependent expression of antiapoptosis proteins. In
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the absence of TRAF2-dependent NF-kB activation,
TNFR1 will elicit efficient stimuli towards TRADD–
FADD, and activation of caspases that result in efficient
proapoptotic signals (Wajant et al., 2001; Chen and
Goeddel, 2002). Importantly, TRAF2-elicited signals
are dependent upon its availability/stability, which is
regulated by c-IAP-1 (Li et al., 2002) and Siah2
(Habelhah et al., 2002), RING-finger proteins with
potent E3 ligase activity. Prolonged TRAF2 stability
under stress conditions results in protection of cells from
apoptosis, whereas accelerated degradation reduces
antiapoptosis signaling, resulting in a higher fraction
of cells that undergo apoptosis (Habelhah et al., 2002).
Consequently, owing to the nature of its stability, the
availability of TRAF2 appears to play an important role
in the regulation of the cell’s ability to undergo
apoptosis via TNF signaling.
It is of interest that progression of melanoma is often
accompanied in a shift in cell’s ability to undergo TNF-
mediated apoptosis. Whereas early-phase melanomas
appear to utilize the TNF pathway, late-phase melano-
mas do not (Ivanov and Ronai, 1999). Further, elevated
TRAF2 expression has been often found in various
human tumors, including melanomas (Devergne et al.,
1996; Zapata et al., 2000; Murray et al., 2001). The
degree of TRAF2 expression following exposure of
melanoma cells to treatment correlates with the degree
of their resistance to apoptosis. Along these lines,
expression of the dominant-negative form of TRAF2,
which lacks its RING domain, suffices to sensitize
melanoma cells to treatment (Ivanov et al., 2001b).
While further highlighting the importance of TRAF2 in
regulating melanoma cells’ ability to undergo apoptosis,
these observations also imply that factors that play
important roles in regulating TRAF2 stability and
activity may undergo changes in the course of melano-
ma progression, explaining the impairment of TNF-
mediated cell death.
Inhibitors of apoptosis and FLIP
Inhibitors of apoptosis (IAPs) physically interact with a
variety of proapoptosis proteins and stuppress apoptosis
induced by different stimuli. Members of the IAP family
are characterized by one to three tandem baculovirus
IAP repeats (BIR); most also possess a carboxyl-
TNFR1
TNFα

















Figure 4 Changes in TNF signaling in melanomas. Whereas TNFa’s ability to elicit antiapoptotic signals is the predominant cascade,
alternate TNF-related signals that allow the activation of caspases and execution of death signaling is attenuated in advanced
melanomas. Common to advanced melanomas is the high level of TRAF2 expression, which results in constitutively active stress
kinases and IKK cascades, thereby resulting in the elevated levels of transcriptionally active NF-kB
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terminal RING-finger motif (Miller, 1999). The anti-
apoptosis activity of several IAPs is based on their
ability to inhibit caspases. Human X-chromosome-
linked IAP (X-IAP), for example, inhibits active
caspase-3 and -7 and Apaf-1–cytochrome c-mediated
activation of caspase-9. Common to melanomas is their
upregulation of IAPs and downregulation of their
effectors. For example, X-IAP is highly expressed in
human melanomas (Zhang et al., 2001). Via their
RING-finger, IAPs serves as E3 ubiquitin ligases to
promote the ubiquitination and proteasome-mediated
degradation of the caspases that they bind (Yang et al.,
2000; Suzuki et al., 2001). ML-IAP is another member
of this family, which is preferentially expressed in
human melanomas (Vucic et al., 2000, 2002). IAPs are
themselves regulated by proteins that suppress their
antiapoptosis activity. For example, SMAC/DIABLO is
processed during apoptosis into the active form and
released from mitochondria to the cytosol, where it
binds IAPs, preventing them from inhibiting caspases
(Deveraux and Reed, 1999). Another regulator of death
receptor-mediated apoptosis that is often upregulated in
melanomas is c-FLIP (FLICE-inhibitory protein),
which serves as a negative inhibitor of caspase-8 (Irmler
et al., 1997; Krueger et al., 2001; Thome and Tschopp,
2001). In contrast, Apaf1, which is negatively regulated
by IAPs, is silenced because of methylation in advanced
melanomas (Soengas et al., 2001). Transcription control
of FLIP expression is dependent on NF-kB (Michaeu
et al., 2001), while proteasome-dependent degradation
of FLIP may additionally sensitize cancer cells to
TRAIL-mediated apoptosis (Kim et al., 2002).
Summary
Transcription factors appear to serve as the master
regulators of apoptosis pathways. Therefore, their
inactivation as a result of attenuated transcription or
their activation because of altered post-translational
modifications results in altered composition of their
heterodimerization partners. Consequently, their ability
to exert selective activation of a subset of genes
associated with a specific phenotype, such as resistance
to apoptosis, is modified. That key transcription factors
such as NF-kB and c-Jun are able to exert both pro- and
antiapoptosis functions provide strong support for the
role of transcriptional switch as a primary factor in
determining the nature of the apoptosis cascade and
concomitant sensitization of melanoma cells to treat-
ment. Examples provided in this review for mechanisms
that govern Fas, TRAIL-receptors and TNF-receptors,
three of the major apoptosis pathways, further support
the importance of transcriptional regulation in deter-
mining which of the pathways will prevail and its
functionality. This knowledge should allow design of
better targets for treatment, which would enable
selective modification of apoptotic cascade in specific
tumor environments.
Acknowledgements
Support by NCI grants (CA55995 and CA559908 to ZR) and a
Sharp Foundation grant (to ZR) is gratefully acknowledged.
References
Adams JM and Cory S. (1998). Science, 281, 1322–1326.
Alarcon-Vargas D and Ronai Z. (2002). Carcinogenesis, 23,
541–547.
Andreola G, Rivoltini L, Castelli C, Huber V, Perego P,
Deho P, Squarcina P, Accornero P, Lozupone F,
Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M,
Parmiani G and Fais S. (2002). J. Exp. Med., 195,
1303–1316.
Aoki K, Akyurek LM, San H, Leung K, Parmacek MS, Nabel
EG and Nabel GJ. (2000). Mol. Ther., 1, 555–565.
Aragane Y, Maeda A, Cui CY, Tezuka T, Kaneda Y and
Schwarz T. (2000). J. Invest. Dermatol., 115, 1008–1014.
Arai H, Gordon D, Nabel EG and Nabel GJ. (1997). Proc.
Natl. Acad. Sci. USA, 94, 13862–13867.
Ashkenazi A and Dixit VM. (1998). Science, 281,
1305–1308.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA,
Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J,
Koeppen H, Shahrokh Z and Schwall RH. (1999). J. Clin.
Invest., 104, 155–162.
Baldwin Jr AS. (1996). Annu. Rev. Immunol., 14, 649–683.
Bargonetti J and Manfredi JJ. (2002) Curr. Opin. Oncol., 14,
86–91.
Baud V and Karin M. (2001). Trends Cell Biol., 11, 372–377.
Bhoumik A, Ivanov V and Ronai Z. (2001). Clin. Cancer Res.,
7, 331–342.
Beg AA and Baltimore D. (1996). Science, 274, 782–784.
Bhoumik A, Huang T-G, Ivanov V, Gangi L, Qiao RF, Woo
SLC, Chen S-H and Ronai Z. (2002). J. Clin. Invest., 110,
643–650.
Bullani RR, Wehrli P, Viard-Leveugle I, Rimoldi D, Cerottini
JC, Saurat JH, Tschopp J and French LE. (2002). Melanoma
Res., 12, 263–270.
Castellano M and Parmiani G. (1999). Melanoma Res., 9,
421–432.
Celebi JT, Shendrik I, Silvers DN and Peacocke M. (2000). J.
Med. Genet., 37, 635–657.
Chan H, Bartos DP and Owen-Schaub LB. (1999). Mol. Cell.
Biol., 19, 2098–2108.
Chen G and Goeddel D. (2002). Science, 296, 1634–1635.
Daniel PT, Wieder T, Sturm I and Schulze-Osthoff K. (2001).
Leukemia, 15, 1022–1032.
Darnell Jr JE. (2002). Nat. Rev. Cancer, 2, 740–749.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,
Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis
N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R,
Hughes J, Kosmidou V, Menzies A, Mould C, Parker A,
Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H,
Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-
Jones K, Maitland N, Chenevix-Trench G, Riggins GJ,
Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A,
Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF,
Darrow TL, Paterson H, Marais R, Marshall CJ,
Death receptors and melanoma resistance to apoptosis
VN Ivanov et al
3159
Oncogene
Wooster R, Stratton MR, Futreal PA. (2002). Nature, 417,
949–954.
Deveraux QL and Reed JC. (1999). Genes Dev., 13,
239–252.
Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q,
Srinivasula SM, Alnemri ES, Salvesen GS and Reed JC.
(1998). EMBO J., 17, 2215–2223.
Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen
MF, Kieff E and Mosialos G. (1996). Mol. Cell. Biol., 16,
7098–7108.
Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H,
Angel P and Krammer PH. (2000). Mol. Cell. Biol., 20,
7826–7837.
Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-
Schaub L, Buzaid AC and Grimm EA. (1999). Melanoma
Res., 9, 261–272.
Elsing A and Burgert HG. (1998). Proc. Natl. Acad. Sci. USA,
95, 10072–10077.
Fan M and Chambers TC. (2001). Drug Resist. Updat., 4,
253–267.
Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY,
Thomas WD, Nguyen T and Hersey P. (2001). J. Immunol.,
166, 5337–5345.
Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin
MZ. (1998). J. Immunol., 161, 2833–2840.
Habelah H, Frew IJ, Laine A, Janes PW, Relaix F, Sassoon D,
Bowtell DDL and Ronai Z. (2002). EMBO J., 21,
5756–5765.
Hagemann C and Blank JL. (2001). Cell Signal., 13, 863–875.
Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M,
French LE, Schneider P, Bornand T, Fontana A, Lienard D,
Cerottini J and Tschopp J. (1996). Science, 274,
1363–1366.
Helmbach H, Rossmann E, Kern MA and Schadendorf D.
(2001). Int. J. Cancer, 93, 617–622.
Herlyn M and Satyamoorthy K. (1996) Am. J. Pathol., 149,
739–744.
Herr I and Debatin KM. (2001). Blood, 98, 2603–2614.
Hersey P and Zhang XD. (2001). Nature Rev. Cancer, 1,
142–150.
Holtz-Heppelmann CJ, Algeciras A, Badley AD and Paya CV.
(1998). J. Biol. Chem., 273, 4416–4423.
Hsu H, Shu HB, Pan MG and Goeddel DV. (1996). Cell, 84,
299–308.
Hsu SC, Gavrilin MA, Lee HH, Wu CC, Han SH and Lai MZ.
(1999a). Eur. J. Immuno.l, 29, 2948–2956.
Hsu SC, Gavrilin MA, Tsai MH, Han J and Lai MZ. (1999b).
J. Biol. Chem., 274, 25769–25776.
Hug H. (1997). Biol. Chem., 378, 1405–1412.
Igney FH and Krammer PH. (2002). Nat. Rev. Cancer, 2,
277–288.
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K,
Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C,
Rimoldi D, French LE and Tschopp J. (1997). Nature, 388,
190–195.
Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-
Schaub LB, Levy D, Horvath CM and Ronai Z. (2001a).
Mol. Cell, 7, 517–528.
Ivanov VN, Fodstad O and Ronai Z. (2001b). Oncogene, 20,
2243–2253.
Ivanov VN, Kehrl JH and Ronai Z. (2000a). Oncogene, 19,
933–942.
Ivanov VN, Krasilnikov M and Ronai Z. (2002). J. Biol.
Chem., 277, 4932–4944.
Ivanov VN, Lee RK, Podack ER and Malek TR. (1997).
Oncogene, 14, 2455–2464.
Ivanov VN and Ronai Z. (1999) J. Biol. Chem., 274,
14079–14089.
Ivanov VN and Ronai Z. (2000b). Oncogene, 19, 3003–3012.
Johnstone RW, Ruefli AA and Lowe SW. (2002). Cell, 108,
153–164.
Karin M, Cao Y, Greten FR and Li Z-W. (2002). Nat. Rev., 2,
301–310.
Karin M and Lin A. (2002). Nat. Immunol., 3, 221–227.
Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi
A and Green DR. (1998). Mol. Cell, 1, 543–551.
Kim Y, Suh N, Sporn M and Reed JC. (2002). J. Biol. Chem.,
277, 22320–22329.
Kirchhoff S, Sebens T, Baumann S, Krueger A, Zawatzky R,
Li-Weber M, Meinl E, Neipel F, Fleckenstein B and
Krammer PH. (2002). J. Immunol., 168, 1226–1234.
Kitada S, Pedersen I, Schimmer A and Reed J. (2002).
Oncogene, 21, 3459–3474.
Kolbus A, Herr I, Schreiber M, Debatin KM, Wagner EF and
Angel P. (2000). Mol. Cell. Biol., 20, 575–582.
Kumar S and Vaux DL. (2002). Science, 297, 1290–1292.
Krammer PH. (2000). Nature, 407, 789–795.
Krasilnikov M, Ivanov VN, Dong J., Ronai Z. (2003). Mol.
Cell. Biol. (In press).
Krueger A, Baumann S, Krammer P and Kirchhoff S. (2001).
Mol. Cell. Biol., 21, 8247–8254.
Lassus P, Opitz-Araya X and Lazebnik Y. (2002). Science,
297, 1352–1354.
Li X, Yili Y and Ashwell JD. (2002). Nature, 416, 345–347.
Li-Weber M, Laur O, Dern K and Krammer PH. (2000). Eur.
J. Immunol., 30, 661–670.
Locksley RM, Killeen N and Lenardo MJ. (2001). Cell, 104,
487–501.
Mandic A, Viktorsson K, Heiden T, Hansson J and Shoshan
MC. (2001). Melanoma Res., 11, 11–19.
Marsters SA, Pitti RA, Sheridan JP and Ashkenazi A. (1999).
Recent Prog. Horm. Res., 54, 225–234.
Martinou JC and Green DR. (2001). Nat. Rev. Mol. Cell. Biol.,
2, 63–67.
Matsui K, Fine A, Zhu B, Marshak-Rothstein A and Ju ST.
(1998). J. Immunol., 161, 3469–3473.
McClure RF, Heppelmann CJ and Paya CV. (1999). J. Biol.
Chem., 274, 7756–7762.
Micheau O, Lens S, Gaide O, Alevizopoulos K and Tschopp J.
(2001). Mol. Cell. Biol., 21, 5299–5305.
Miller LK. (1999). Trends Cell Biol., 9, 323–328.
Minamoto T, Buschmann T, Habelhah H, Matusevich E,
Tahara H, Boerresen-Dale AL, Harris C, Sidransky D and
Ronai Z. (2001). Oncogene, 20, 3341–3347.
Mittelstadt PR and Ashwell JD. (1998). Mol. Cell. Biol., 18,
3744–3751.
Morgan M, Thorburn J, Pandolfi PP and Thorburn A. (2002).
J. Cell. Biol., 157, 975–984
Murray PG, Flavell JR, Baumforth KR, Toomey SM, Lowe
D, Crocker J, Ambinder RF and Young LS. (2001).
J. Pathol., 194, 158–164.
Muschen M, Warskulat U and Beckmann MW. (2000).
J. Mol. Med., 78, 312–325.
Nagata S. (1997). Cell, 88, 355–365.
Nagata S. (1999). Annu. Rev. Genet., 33, 29–55.
Nicholson DW. (1999). Cell Death Differ., 6, 1028–1042.
Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS,
Jove R and Yu H. (2001). Cancer Res., 61, 3276–3280.
O’Connell J, Bennett MW, O’Sullivan GC, Collins JK and
Shanahan F. (1999). Immunol. Today, 20, 46–52.
Owen-Schaub LB, van Golen KL, Hill LL and Price JE.
(1998). J. Exp. Med., 188, 1717–1723.
Death receptors and melanoma resistance to apoptosis
VN Ivanov et al
3160
Oncogene
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee
SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW,
Kruzel E et al. (1995). Mol. Cell. Biol., 15, 3032–3040.
Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann
E and Tschopp J. (1999). EMBO J., 18, 1824–1831.
Pollack IF, Erff M and Ashkenazi A. (2001). Clin. Cancer
Res., 7, 1362–1369.
Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B,
Gelinas C, Fuchs EJ and Bedi A. (2001). Nat. Cell Biol., 3,
409–416.
Reichmann E. (2002). Cancer Biol., 12, 309–315.
Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M and
Herlyn M. (1998). Oncogene, 16, 523–531.
Rothe M, Sarma V, Dixit V and Goeddel D. (1995). Science,
269, 1424–1427.
Rutberg SE, Goldstein IM, Yang YM, Stackpole CW and
Ronai Z. (1994). Mol. Carcinog., 10, 82–87.
Santourlidis S, Warskulat U, Florl AR, Maas S, Pulte T,
Fischer J, Muller W and Schulz WA. (2001). Mol. Carcinog.,
32, 36–43.
Sato T, Irie S, Kitada S and Reed JC. (1995). Science, 268,
411–415.
Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-
Deiry WS, Herlyn M and Halazonetis TD. (2000). Cell
Growth Differ., 11, 467–474.
Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH and
Peter ME. (1999). J. Biol. Chem., 274, 22532–22538.
Shaulian E and Karin M. (2002). Nat. Cell Biol., 4,
E131–E136.
Shin MS, Kim HS, Lee SH, Lee JW, Song YH, Kim YS, Park
WS, Kim SY, Lee SN, Park JY, Lee JH, Xiao W, Jo KH,
Wang YP, Lee KY, Park YG, Kim SH, Lee JY and Yoo NJ.
(2002). Oncogene, 21, 4129–4136.
Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY,
Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ and Lee
SH. (1999). Am. J. Pathol., 154, 1785–1791.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M,
Opitz-Araya X, McCombie R, Herman JG, Gerald WL,
Lazebnik YA, Cordon-Cardo C and Lowe SW. (2001).
Nature, 409, 207–211.
Soubrane C, Mouawad R, Antoine EC, Verola O,
Gil-Delgado M and Khayat D. (2000). Br. J. Dermatol.,
143, 307–312.
Suzuki Y, Nakabayashi Y and Takahashi R. (2001). Proc.
Natl. Acad. Sci. USA, 98, 8662–8667.
Thomas WD and Hersey P. (1998). J. Immunol., 161,
2195–2200.
Thome M and Tschopp J. (2001). Nat. Rev. Immunol., 1,
50–58.
Tollefson AE, Toth K, Doronin K, Kuppuswamy M,
Doronina OA, Lichtenstein DL, Hermiston TW, Smith
CA and Wold WSM. (2001). J. Virol., 75, 8875–8887.
van Dam H and Castellazzi M. (2001). Oncogene, 20,
2453–2464.
van Dam H, Huguier S, Kooistra K, Baguet J, Vial E, van der
Eb AJ, Herrlich P, Angel P and Castellazzi M. (1998). Genes
Dev., 12, 1227–1239.
Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkho-
dayan S, Fairbrother WJ and Dixit VM. (2002). J. Biol.
Chem., 277, 12275–12279.
Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS and Dixit
VM. (2000). Curr. Biol., 10, 1359–1366.
Wajant H, Henkler F and Scheurich P. (2001). Cell Signal., 13,
389–400.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS,
Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C,
Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch
DH. (1999). Nat. Med., 5, 157–163.
Weinstein-Oppenheimer CR, Blalock WL, Steelman LS,
Chang F and McCubrey JA. (2000). Pharmacol. Ther., 88,
229–279.
Worth LL, Lafleur EA, Jia SF and Kleinerman ES. (2002).
Oncogene, 9, 823–827.
Yang Y, Fang S, Jensen JP, Weissman AM and Ashwell JD.
(2000). Science, 288, 874–877.
Zamzami N and Kroemer G. (2001). Nat. Rev. Mol. Cell. Biol.,
2, 67–71.
Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K,
Monks A, McCloskey N, Gordon J, Kipps TJ, Gascoyne
RD, Shabaik A and Reed JC. (2000). J. Immunol., 165,
5084–5096.
Zhang XD, Franco A, Myers K, Gray C, Nguyen T and
Hersey P. (1999). Cancer Res., 59, 2747–2753.
Zhang XD, Zhang XY, Gray CP, Nguyen T and Hersey P.
(2001). Cancer Res., 61, 7339–7348.
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman
WH, Tom E, Mack DH and Levine AJ. (2000). Genes Dev.,
14, 981–993.
Zheng Y, Ouaaz F, Bruzzo P, Singh V, Gerondakis S and Beg
AA. (2001). J. Immunol., 166, 4949–4957.
Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ and
Eng C. (2000). Am. J. Pathol., 157, 1123–1128.
Death receptors and melanoma resistance to apoptosis
VN Ivanov et al
3161
Oncogene
